Drug Detail

Information about Bezuclastinib plus Sunitinib

Generic Name	Bezuclastinib plus Sunitinib
IND	CGT9486
Brand Name (US)
Manufacturer	Cogent Biosciences
Drug Type
Delivery	Oral
Approval Status
Indications
Overall Strategy	Inhibit KIT/PDGFRa
Strategy	Inhibit all resistant KIT/PDGFRa mutations
Drug Category	KIT inhibitor

Bezuclastinib
• Specifically targets KIT mutations
including exon 17 D816V
• Selective versus other targets including
wild-type KIT, PDGFRα, VEGFR2, FLT3 and
CSF1R